Autologous CGF Kit for Knee Osteoarthritis

This clinical trial is set up to find out if a new treatment using an autologous platelet-rich concentrated growth factor (CGF) preparation kit can help people with knee osteoarthritis. The study targets individuals who have been diagnosed with this condition, which causes joint pain and stiffness. Researchers hope to see if this new treatment can offer better relief from symptoms and improve knee function compared to a standard treatment using platelet-rich plasma (PRP). This research is important because it could lead to a new way to manage knee osteoarthritis, providing better pain relief and improved mobility for those affected. Participants in the study will receive three injections directly into the knee joint, either with the CGF or PRP, once a week. Throughout the study, they will fill out special surveys like the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and a Visual Analog Scale (VAS) to measure pain and knee function. Participants will be closely monitored to ensure their safety and to track any side effects. By doing so, the study aims to gather clear evidence on whether the CGF treatment is more effective than the current PRP approach.